Modelling is an essential part of health economic analyses. It is a central tool for authorities, experts and payers to support decision-making regarding healthcare resource utilization.
Modelling is an essential part of health economic analyses. It is a central tool for authorities, experts and payers to support decision-making regarding healthcare resource utilization. With the help of modelling, fragmented research data, observations, and experiences, as well as justified assumptions, are compiled into a synthesis that aims to anticipate and predict the impact of healthcare interventions on individuals, patient groups, healthcare and society.
Modelling not only answers the decision maker’s question about the most likely outcome, but also the probability of extreme scenarios, as well as the credible range of results. In its most general form, modelling relates to the cost-effectiveness of an intervention. This means that the costs are examined together with the health benefits of the intervention. Another common target of modelling is the budget impact of an intervention. In this case, the focus is on the intervention’s impact on the use of resources. These can be even directly related to the intervention, or indirectly to the entire treatment path of a patient.
Medaffcon has the ability to complete modelling projects from the localization of the customer’s ready global core models to the comprehensive construction of models from the beginning. We have been doing modelling for over 10 years, providing our customers with an effective tool to support decision making.
“Modeling enables the combination of information from multiple sources and thus the evaluation of effectiveness and cost-effectiveness. The analysis can be based on any kind of information, such as the results of clinical trials or real world data.”
“The purpose of modelling is to provide tools for the clients and decision makers for managing and predicting future uncertainty. Modelling provides information for decision-making and for discussions with public authorities and healthcare payers.”
Read more about our interactive value tools that combine health economic modelling, real world evidence and data science into one easy to use product.
Coming up soon, Copenhagen will be the center of health economics as more than five thousand pharmaceutical and healthcare professionals gather for the ISPOR conference. ISPOR has been well known, especially among health economists. However, this years’ top trends real-world data (RWD) and real-world evidence (RWE) attract even wider audience.
Medaffcon has added Swedish healthcare registries to its capabilities as it continues to pursue growth and facilitate data utilisation by providing pharmaceutical companies access to rich and relevant healthcare data.
Timo Karvinen joined Medaffcon’s Market Access team as an expert in the beginning of May. In addition to his extensive expertise, he also brings a whole new service concept to Medaffcon.
Health Economist
Market Access Lead
MSc (Health Economics)
+358 44 326 4477
heini.honkanen@medaffcon.fi
Heini joined Medaffcon’s Market Access team in the spring of 2018. Heini holds master’s degree in health and social sciences, majoring in Health Economics. Prior to moving into the field of pharmacoeconomics, Heini has worked as an entrepreneur in the health and sport industry. At Medaffcon, Heini works as Market Access Lead with various market access processes and health technology assessments.
Heini has a wide range of expertise in the price and reimbursement processes and health technology assessments in multiple therapy areas. Heini is interested in the possibilities to turn data into understandable information to support healthcare decision-making and thus increase the patient’s well-being. Together with her team and clients she strives to facilitate the provision of bespoke solutions for customers’ pricing and market access needs.